Rashmi K Murthy
Assistant Professor
Department of Breast Medical Oncology
MD Anderson Cancer Center
United States of America
Biography
Degree-Granting Education: 2008 :University of Alabama School of Medicine, Birmingham, AL, USA, MD, Medicine 2004 :University of Pennsylvania, Philadelphia, PA, USA, Masters, Bioethics, Bioethics 2003 :University of Alabama-Birmingham (UAB), Birmingham, AL, USA, BA, Philosophy Postgraduate Training: 2011-2014 :Clinical Fellowship, Hematology and Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 2008-2011 :Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, TX Honors & Awards: 2013 :Allison and Brian Grove Endowed Fellowship Award, The University of Texas MD Anderson Cancer Center. 2012 :ASCO Foundation Merit Award, American Society of Clinical Oncology 2012 :Allison and Brian Grove Endowed Fellowship Award, The University of Texas MD Anderson Cancer Center. 2008 :Tinsley Harrison Research Society, University of Alabama School of Medicine, Birmingham, AL. 2007 ;Young Investigator Award, Chicago Supportive Oncology Conference 2005 :Medical Student Research Day Finalist, University of Alabama School of Medicine. 2005 :Cancer Research Experiences for Students, The University of Alabama at Birmingham 2003 :UAB CARES (Cancer Research Experiences for Students), University of Alabama, Birmingham, Alabama. 2000 :Early Medical School Acceptance Program, The University of Alabama at Birmingham.
Research Interest
Breast Medical Oncology, oncology.
Publications
-
Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 159 (2) :367-74, 2016. e-Pub 2016.
-
Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol 3 (4) :509-515, 2017
-
Fujii T, Kogawa T, Wu J, Sahin AA, Liu DD, Chavez-MacGregor M, Giordano SH, Raghavendra A, Murthy RK, Tripathy D, Shen Y, Yamal JM, Ueno NT Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy Br J Cancer 116 (4) :509-514, 2017
